Conformationally Constrained Spiro <i>C</i>‐Arylglucosides as Potent and Selective Renal Sodium‐Dependent Glucose Co‐transporter 2 (SGLT2) Inhibitors

Abstract

Sodium glucose co-transporter 2 (SGLT2) is an emerging target for the treatment of type 2 diabetes mellitus (DM2). Here, the synthesis and preliminary biological evaluation of a series of potent, selective SGLT2 inhibitors, derived from a rigid spiro C-arylglucoside scaffold, is described. Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.